These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Gauthier J; Turtle CJ Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831 [TBL] [Abstract][Full Text] [Related]
3. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. Hay KA Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609 [TBL] [Abstract][Full Text] [Related]
4. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292 [TBL] [Abstract][Full Text] [Related]
5. Toxicities of chimeric antigen receptor T cells: recognition and management. Brudno JN; Kochenderfer JN Blood; 2016 Jun; 127(26):3321-30. PubMed ID: 27207799 [TBL] [Abstract][Full Text] [Related]
6. CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity. Jess J; Yates B; Dulau-Florea A; Parker K; Inglefield J; Lichtenstein D; Schischlik F; Ongkeko M; Wang Y; Shahani S; Cullinane A; Smith H; Kane E; Little L; Chen D; Fry TJ; Shalabi H; Wang HW; Satpathy A; Lozier J; Shah NN J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295816 [TBL] [Abstract][Full Text] [Related]
7. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. Kochenderfer JN; Somerville RPT; Lu T; Shi V; Bot A; Rossi J; Xue A; Goff SL; Yang JC; Sherry RM; Klebanoff CA; Kammula US; Sherman M; Perez A; Yuan CM; Feldman T; Friedberg JW; Roschewski MJ; Feldman SA; McIntyre L; Toomey MA; Rosenberg SA J Clin Oncol; 2017 Jun; 35(16):1803-1813. PubMed ID: 28291388 [TBL] [Abstract][Full Text] [Related]
8. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies. Liu J; Zhong JF; Zhang X; Zhang C J Hematol Oncol; 2017 Jan; 10(1):35. PubMed ID: 28143567 [TBL] [Abstract][Full Text] [Related]
9. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662 [TBL] [Abstract][Full Text] [Related]
10. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861 [TBL] [Abstract][Full Text] [Related]
11. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Hill JA; Seo SK Blood; 2020 Aug; 136(8):925-935. PubMed ID: 32582924 [TBL] [Abstract][Full Text] [Related]
12. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Brudno JN; Kochenderfer JN Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964 [TBL] [Abstract][Full Text] [Related]
13. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia. Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660 [TBL] [Abstract][Full Text] [Related]
14. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Hay KA; Hanafi LA; Li D; Gust J; Liles WC; Wurfel MM; López JA; Chen J; Chung D; Harju-Baker S; Cherian S; Chen X; Riddell SR; Maloney DG; Turtle CJ Blood; 2017 Nov; 130(21):2295-2306. PubMed ID: 28924019 [TBL] [Abstract][Full Text] [Related]
15. Promises and limitations of nanoparticles in the era of cell therapy: Example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells. Jakobczyk H; Sciortino F; Chevance S; Gauffre F; Troadec MB Int J Pharm; 2017 Nov; 532(2):813-824. PubMed ID: 28764981 [TBL] [Abstract][Full Text] [Related]
16. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. Liu Y; Chen X; Han W; Zhang Y Drugs Today (Barc); 2017 Nov; 53(11):597-608. PubMed ID: 29451276 [TBL] [Abstract][Full Text] [Related]
18. Toxicities of CD19 CAR-T cell immunotherapy. Hirayama AV; Turtle CJ Am J Hematol; 2019 May; 94(S1):S42-S49. PubMed ID: 30784102 [TBL] [Abstract][Full Text] [Related]
19. Adoptive therapy with CAR redirected T cells for hematological malignancies. Li S; Yang Z; Shen J; Shan J; Qian C Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302 [TBL] [Abstract][Full Text] [Related]
20. CD19-Targeted T Cells for Hematologic Malignancies: Clinical Experience to Date. Davila ML; Sauter C; Brentjens R Cancer J; 2015; 21(6):470-4. PubMed ID: 26588678 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]